November 9, 2020 -- Pierre Fabre has initiated a phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product, W0180, a monoclonal antibody (mAb) targeting the V-domain immunoglobulin suppressor of T-cell activation pathway.
The phase I open-label, multicenter clinical trial will involve sites in France and Spain.
VISTA is an immune-checkpoint molecule that is highly expressed in tumor microenvironments and is a negative regulator of T-cell responses. VISTA expression is also increased after treatment with anti-programmed cell death 1/ligand 1 (PD-1/L1) and anti-cytotoxic T-lymphocyte-associated protein 4.
W0180 is an antibody-targeting VISTA that when given to patients as a single agent or in combination with anti-PD-1/L1 therapy has potential in multiple cancer indications, including those with myeloid immunosuppressive infiltrates where the VISTA pathway is expressed.
Copyright © 2020 scienceboard.net